SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-010790
Filing Date
2024-03-13
Accepted
2024-03-13 07:55:15
Documents
16
Period of Report
2024-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20240313.htm   iXBRL 8-K 33222
2 EX-99.1 exhibit-991031324.htm EX-99.1 125001
6 GRAPHIC logo.gif GRAPHIC 43773
  Complete submission text file 0001628280-24-010790.txt   360740

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20240313.xsd EX-101.SCH 1943
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20240313_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20240313_pre.xml EX-101.PRE 12547
18 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20240313_htm.xml XML 2811
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 24744604
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)